Bacterial consortium therapy for prevention of recurrent c difficile infection
About The Study: Among adults with laboratory-confirmed Clostridioides difficile infection (CDI) with one or more prior CDI episodes in the last six months and those with primary CDI at high risk for recurrence, high-dose VE303 (a novel oral microbiome-directed therapy composed of nonpathogenic, nontoxigenic, commensal strains of Clostridia) prevented recurrent CDI compared with placebo. A larger, phase 3 study is needed to confirm these findings.
Authors: Jeffrey L. Silber, M.D., of Vedanta Biosciences Inc., in Cambridge, Massachusetts, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2023.4314)
Editor’s ...










